Du är här

2015-09-07

Basilea Pharmaceutica AG: Basilea announces development of inhaled dosage form of its Gram-negative antibiotic BAL30072 as part of European iABC program

Basilea Pharmaceutica AG / Basilea announces development of inhaled dosage
form of its Gram-negativeantibiotic BAL30072 as part of European iABC program
. Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is
solely responsible for the content of this announcement.
* Start of "inhaled Antibiotics in Bronchiectasis and Cystic fibrosis" (iABC)
program to develop new antibiotic treatments for cystic fibrosis and
bronchiectasis

Basel, Switzerland, September 7, 2015

- Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that an inhaled
formulation of its antibiotic BAL30072 will be developed as part of a new
Europe-wide program focusing on new antibiotics that could improve the lives
of patients with cystic fibrosis and bronchiectasis. BAL30072 is an
investigational monosulfactam antibiotic within-vitro
andin-vivo
activity against many clinically relevant multidrug-resistant Gram-negative
bacteria.

The iABC (inhaled Antibiotics in Bronchiectasis and Cystic fibrosis)
consortium, which includes world-leading lung specialists from across Europe,
will develop new inhaled antibiotics to manage chronic lung infection, the
main cause of disease and mortality in patients with cystic fibrosis and
bronchiectasis.

The new drugs are being developed in response to an urgent need for new forms
of inhaled antibiotics. They are expected to improve patients' quality of
life by reducing lung infections and flare-ups, improving lung function, and
overcoming antibacterial resistance which frequently occurs in patients with
these conditions.

Prof. Achim Kaufhold, Basilea's Chief Medical Officer, stated: "We are pleased
to work with the iABC consortium within the European IMI, focusing on the
high medical need associated with resistant Gram-negative infections that
affect cystic fibrosis and bronchiectasis patients." He added: "The
development of an inhaled version of BAL30072 as a targeted treatment option
for chronic lung infections may provide a new treatment option for these
patients. The project will initially include pre-clinical development
activities in preparation of clinical phase 1 studies."

The five-year iABC program is part of the European New Drugs for Bad Bugs
(ND4BB) program and will also establish the first European patient register
for bronchiectasis, providing a platform to improve the quality of care for
patients across Europe as well as making it easier to develop and trial new
drugs.

The iABC consortium, which is led by researchers from the School of Medicine,
Dentistry and Biomedical Sciences, and the School of Pharmacy at Queen's
University Belfast with EFPIA*partners Basilea and Novartis is funded by the
European Commission through the Innovative Medicines Initiative (IMI) and
through contributions by EFPIA companies. The total funding for BAL30072
related work will be approximately EUR 11 million of which Basilea
contributes about half. The consortium involves researchers from 20
organizations in eight countries across Europe.

About cystic fibrosis and bronchiectasis

Cystic fibrosis (CF) is a genetic disease that blocks a patient's lungs and
digestive system, affecting approximately 36,000 people in the European
Union. Chronic bacterial pulmonary infection leading to an irreversible
decline in lung structure and function is the main cause of mortality and
morbidity in patients with CF.Pseudomonas aeruginosa
is the most frequently isolated pathogen, chronically infecting up to 80% of
adult patients. More than 95% of deaths in patients with cystic fibrosis are
due to respiratory failure, often as a result of chronic lung infection.

Bronchiectasis (BE) is a group of diseases in which a person's airways become
damaged and scarred. In developed countries, BE affects from 4 per 100,000
young adults to nearly 300 per 100,000 persons 75 years and older. In 2012 it
was calculated that 2.4 million of patients worldwide were affected by BE,
and estimated to grow to 3 million in 2020. Patients with BE suffer from
similar symptoms as patients with CF. Estimates suggest that the airways of
almost all patients with bronchiectasis are chronically infected with
pathogenic bacteria. More than 30% of the BE patients suffer from
chronicPseudomonas aeruginosa
infections.

About the iABC consortium

The iABC consortium involves researchers from Northern Ireland, Scotland,
England, Spain, Germany, France, Italy, Belgium, the Netherlands and
Switzerland.

Organisations involved in the iABC consortium are Queen's University Belfast,
Belfast Health and Social Care Trust, University Medical Center Utrecht,
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e. V.,
Hannover, Rijksuniversiteit Groningen, Servicio Madrileño de Salud, Madrid,
Universitair Ziekenhuis Antwerpen, University of Dundee, Institut National de
la Santé et de la Recherche, Poitiers, Università degli Studi di Milano,
Hospices Civils de Lyon, Medizinische Hochschule Hannover, Universiteit
Antwerpen, University of Edinburgh, Royal Brompton and Harefield NHS
Foundation Trust, Fundació Clínic per a la Recerca Biomèdica, Barcelona,
Papworth Hospital NHS Foundation Trust, Erasmus Medical Center, Rotterdam,
and the EFPIA companies Basilea Pharmaceutica International Ltd., and
Novartis Pharma AG, Basel.

About IMI, ND4BB and EFPIA

In November 2011, the European Commission launched its Action Plan against the
rising threat from Antimicrobial Resistance, and called for "unprecedented
collaborative research and development efforts to bring new antibiotics to
patients." The New Drugs for Bad Bugs (ND4BB) program was launched within the
Innovative Medicines Initiative (IMI) in direct response to this call. IMI is
a joint undertaking between the European Union and the European Federation of
Pharmaceutical Industries and Associations (EFPIA); it constitutes Europe's
largest public-private initiative aiming to accelerate the development of
better and safer medicines for patients. More information:www.imi.europa.eu.

The EFPIA brings together 33 European national pharmaceutical industry
associations as well as 40 leading companies undertaking research,
development and the manufacture in Europe of medicinal products for human
use. More information:www.efpia.eu.

About Basilea

Basilea Pharmaceutica Ltd. is a biopharmaceutical company developing products
that address increasing resistance and non-response to current treatment
options in the therapeutic areas of bacterial infections, fungal infections
and cancer. The company uses the integrated research, development and
commercial operations of its subsidiary Basilea Pharmaceutica International
Ltd. to discover, develop and commercialize innovative pharmaceutical
products to meet the medical needs of patients with serious and potentially
life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in
Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN).
Additional information can be found at Basilea's websitewww.basilea.com.

Disclaimer

This communication expressly or implicitly contains certain forward-looking
statements concerning Basilea Pharmaceutica Ltd. and its business. Such
statements involve certain known and unknown risks, uncertainties and other
factors, which could cause the actual results, financial condition,
performance or achievements of Basilea Pharmaceutica Ltd. to be materially
different from any future results, performance or achievements expressed or
implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is
providing this communication as of this date and does not undertake to update
any forward-looking statements contained herein as a result of new
information, future events or otherwise.

For further information, please contact:

-------------------------------------------------------------
| Media Relations Investor Relations |
| Peer Nils Schröder, PhD Barbara Zink, PhD, MBA |
| |
|Head Public Relations& Head Corporate Development |
|Corporate Communications |
|+41 61 606 1102 +41 61 606 1233 |
|media_relations@basilea.com investor_relations@basilea.com |
-------------------------------------------------------------
This press release can be downloaded fromwww.basilea.com.

References

* European Federation of Pharmaceutical Industries and Associations

Press release (PDF)
http://hugin.info/134390/R/1949998/708837.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Basilea Pharmaceutica AG via Globenewswire

HUG#1949998

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.